AscellaHealth Provides Specialty & Rare Pipeline Digest™ Recap: Navigating the Path to 2024 Groundbreaking Therapies

AscellaHealth Provides Specialty & Rare Pipeline Digest™ Recap: Navigating the Path to 2024 Groundbreaking Therapies

AscellaHealth Provides Specialty & Rare Pipeline Digest™ Recap: Navigating the Path to 2024 Groundbreaking Therapies

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics. Continuing its tradition of providing a quarterly, complimentary, digital source of industry information to support the specialty drug market needs of all stakeholders and decision-makers, AscellaHealth meets the needs of pharmaceutical manufacturers, payers and providers with essential updates on products that may impact millions of individuals living with or affected by rare disease or complex, chronic conditions.

“This timely, thoroughly researched document provides valuable insights and data to fortify our partnerships, assist our clients and support the entire specialty pharmaceutical ecosystem,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth. “As we closed out 2023 and stepped into 2024, this issue becomes a compass, empowering stakeholders to proactively navigate the evolving landscape. It encapsulates our mission, reflecting our commitment to supporting patients and clients with profound industry expertise, thereby guiding decision-making processes with informed insights.”

Dea Belazi, CEO, AscellaHealth, emphasizes the significance of its quarterly Specialty & Rare Pipeline Digest™, stating, “Anticipating further breakthroughs and the introduction of novel, innovative treatments, AscellaHealth moves proactively into 2024, taking the lead in presenting this informative, expert resource. Providing FDA approval status for specialty pharmaceuticals and cell & gene therapies, this publication underscores our mission to enhance treatment access, improve patient care and optimize healthcare outcomes.”

The Specialty & Rare Pipeline Digest™ complements the role of AscellaHealth as a single-source industry partner, providing end-to-end, global solutions which result in the streamlined commercialization of specialty drugs, cost savings for clients and an optimal treatment journey for patients and family caregivers facing the challenges of a rare disease or complex, chronic condition. Core Services include:

  • Pre-Commercialization & Market Access
  • Exclusive Distribution, Wholesale and 3PL Services
  • International Specialty Pharmacy Fulfillment
  • Comprehensive HUB and Patient Support Services

    • Custom Compliance and Persistency Programs
    • Streamlined Prior Authorizations
    • Technology-based Patient Engagement
    • Integrated Copay and Financial Assistance Programs
    • Real-time Rx Data and Analytics
  • Specialty Pharmacy & Medical Benefit Management

Access the latest Specialty & Rare Pipeline Digest™ here.

About AscellaHealth LLC

AscellaHealth, a global healthcare and specialty pharmacy solutions organization, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, including Deloitte Technology Fast 500™ and Inc. 5000, AscellaHealth’s customized, patient-centric approach is built upon proprietary technology processes for end-to-end solutions to streamline the commercialization of specialty medications and proactively address unmet client needs, optimize clinical health outcomes and improve the quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders. Visit


Nicole Dufour

CPR Communications
201.641.1911 x 54

Darcey McDermott, Chief Marketing & Communications Officer